Ariad leukemia drug ponatinib PACE trial in positive data
June 4, 2012, Ariad Pharmaceuticals' experimental leukemia drug called PACE ponatinib in a pivotal clinical trial of positive data. Ariad company said it plans to submit to the FDA in the third quarter regulatory applications.
The study has been submitted to the ASCO meeting. Found in about 54% of the chronic phase of chronic myelogenous leukemia (CML) patients had a major response ponatinib (major response), which means that these patients the bone marrow, of at least 2/3 of the normal. Of these patients, 44% achieved a complete remission.
Are assessed in 64 chronic phase CML patients carrying the T315I mutation, 70% of patients had a major response ponatinib. Do not carry mutations in chronic phase CML patients, the main reaction was 49%.
The trial involved 444 pairs Novartis (Novartis) for Tasigna and Bristol-Myers Squibb (BMS) for Sprycel stops responding patients.
These are often called nilotinib and dasatinib old medicine, is a class called tyrosine kinase inhibitors member. Tyrosine kinases are a class of cells able to play "on" and "off" conversion function of the enzyme.
Riad's drug targets a chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia-associated abnormal tyrosine kinases.
Trial common side effects include rash (32%), low platelet count (35%), dry skin (30%), abdominal pain (20%)
Ariad leukemia drug ponatinib PACE trial in positive data
ReplyDeleteJune 4, 2012, Ariad Pharmaceuticals' experimental leukemia drug called PACE ponatinib in a pivotal clinical trial of positive data. Ariad company said it plans to submit to the FDA in the third quarter regulatory applications.
The study has been submitted to the ASCO meeting. Found in about 54% of the chronic phase of chronic myelogenous leukemia (CML) patients had a major response ponatinib (major response), which means that these patients the bone marrow, of at least 2/3 of the normal. Of these patients, 44% achieved a complete remission.
Are assessed in 64 chronic phase CML patients carrying the T315I mutation, 70% of patients had a major response ponatinib. Do not carry mutations in chronic phase CML patients, the main reaction was 49%.
The trial involved 444 pairs Novartis (Novartis) for Tasigna and Bristol-Myers Squibb (BMS) for Sprycel stops responding patients.
These are often called nilotinib and dasatinib old medicine, is a class called tyrosine kinase inhibitors member. Tyrosine kinases are a class of cells able to play "on" and "off" conversion function of the enzyme.
Riad's drug targets a chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia-associated abnormal tyrosine kinases.
Trial common side effects include rash (32%), low platelet count (35%), dry skin (30%), abdominal pain (20%)
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Ruxolitinib phosphate
INCB018424 sulfate
Baricitinib
AZD-1480
TG-101348
TG101209
CYT387
LY2784544
Baricitinib
WHI-P97